Archean Chemical Q2 FY27 Results: Dates, Metrics, Outlook

Archean Chemical Industries is scheduled to report its Q2 FY27 financial results on October 29, 2026. The September-quarter update is important because the company enters the announcement after reporting higher revenue but lower profit and margins in Q1 FY27. Investors will look for details on bromine, bromine derivatives and industrial salt, which are central to its operating performance. The company has also scheduled an earnings call for November 3, 2026, at 2:30 PM IST. Management representatives including the Managing Director, Chief Financial Officer and DGM Finance are expected to discuss the Q2 and H1 FY27 numbers. The company said the call will be available to shareholders through a pre-registration link, with details also to be hosted on its website.

Q2 FY27 Results Are Due on October 29

The Q2 FY27 period covers July 1, 2026, to September 30, 2026. Earlier updates had noted that a board-meeting intimation for the quarter had not been filed as of September 8, 2026. Under the applicable listing timeline cited in the available information, September-quarter results were required within 45 days of the quarter-end, or by November 14, 2026. The October 29 reporting date therefore provides the formal results update ahead of that outer deadline. The supplied material does not contain the actual Q2 FY27 revenue, profit or margin figures. As a result, the results announcement should not be confused with a confirmed financial outcome before the company releases its filing.

November 3 Earnings Call Will Cover H1 FY27

The November 3 call is scheduled for 2:30 PM IST. It will cover both the Q2 FY27 performance and the first half of FY27. This is relevant because management commentary can provide context that is not fully visible in the financial statements, including segment trends and expense movements. Shareholders will be able to hear from senior management through the announced conference call. The filing includes a pre-registration link, while the company said relevant details would be placed on its website. Archean had previously made available the audio recording of its August 3, 2026 call for the quarter ended June 30, 2026.

Q1 FY27 Sets the Immediate Financial Context

Archean reported consolidated net profit of ₹30.68 crore for the June 2026 quarter, down 23.66% from ₹40.19 crore in the June 2025 quarter. Sales rose 11.92% year-on-year to ₹327.20 crore from ₹292.36 crore. Other company material described Q1 FY27 revenue at ₹332.81 crore, up 11% year-on-year, while standalone revenue was reported at ₹332.10 crore, up 14% year-on-year. These figures relate to different disclosures and reporting bases cited in the available information. The Q1 disclosures also reported consolidated PAT of ₹30.35 crore in one company update. Investors should therefore rely on the company’s Q2 filing for the exact reported basis and comparative numbers.

Profitability Was Lower Despite Revenue Growth

The Q1 results showed that revenue growth did not translate into higher profit. An earnings summary reported earnings per share of ₹2.48, compared with ₹3.25 in Q1 FY26. Net income was reported at ₹30.68 crore, while profit margin fell to 9.2% from 14% a year earlier. The same summary attributed the margin decline to higher expenses. Revenue exceeded analyst estimates by 2.1%, while earnings per share exceeded estimates by 18%, according to the supplied consensus commentary. But the year-on-year decline in earnings highlights why operating costs and pricing will remain key issues in the Q2 discussion.

Bromine Derivatives Supported Q1 Growth

Bromine derivatives were the main growth driver in the June quarter. Revenue from this segment rose 58% year-on-year, according to the Q1 investor presentation. Industrial salt revenue, however, declined 12% year-on-year due to logistics disruptions. The company also said derivatives were EBITDA-positive during the quarter. Archean is a marine chemicals producer focused on bromine and industrial salt for export markets. The relative performance of these businesses matters because a stronger derivatives contribution may support revenue, while salt volumes and logistics can affect the overall mix.

Key Reported Figures at a Glance

Q2 Comparisons Start With Last Year's Base

For the September 2026 quarter, the reported comparison base is Q2 FY26 revenue of ₹239.56 crore and profit of ₹29.04 crore. The available preview did not include a verified analyst estimate for Q2 FY27 revenue or profit. This makes the official release especially important for establishing how the company performed against the prior-year base. The results will also show whether the higher revenue level reported in Q1 carried into the September quarter. Any disclosure on operating profit, costs and exceptional items will help explain the movement in net profit.

Consensus Forecasts Show Mixed Expectations

The supplied consensus outlook for FY27 raised the revenue forecast to ₹1,560 crore from ₹1,520 crore. At the same time, the EPS estimate was lowered to ₹16.33 from ₹21.28. The consensus price target was broadly unchanged at ₹587. The share price was reported at ₹518 after falling 7.7% over the preceding week. These forecasts are not company guidance and should be treated separately from reported financial results. They nonetheless show that expectations for sales have improved while projected per-share profitability has weakened.

Industry Conditions Remain Relevant

The available commentary identified global commodity prices and seasonal output constraints linked to India’s monsoon as factors affecting the company’s operating environment. It also pointed to pricing pressure as a key risk for margins. Archean’s Q1 performance illustrated this issue: revenue increased while profit margin narrowed. Logistics disruptions affecting industrial salt were another reported operational factor. For investors, the Q2 release and subsequent conference call may clarify whether these factors continued through the September quarter. The company has not provided a verified Q2 numerical estimate in the information supplied.

What Investors Can Track After the Release

The October 29 filing will provide the first formal financial view of the September quarter. Investors can compare revenue and net profit with the Q2 FY26 base, as well as assess sequential changes from the June quarter. Segment-level commentary on bromine derivatives and industrial salt will be relevant after their divergent Q1 performance. Margin trends will also be closely watched following the Q1 decline to 9.2%. The November 3 earnings call is the next confirmed event, when management is expected to discuss Q2 and H1 FY27 performance with shareholders.